Juniper Pharmaceuticals to Report Third Quarter 2016 Results on November 15, 2016

BOSTON, Nov. 14, 2016 /PRNewswire/ -- The management team of Juniper Pharmaceuticals, Inc. JNP ("Juniper" or the "Company"), will hold a conference call on November 15, 2016, to discuss the financial results for the third quarter and nine months ended September 30, 2016, as follows:

The teleconference replay will be available at approximately one hour after completion through Tuesday, November 22, 2016, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10095855.

The archived webcast will be available for one year via the aforementioned URLs.

About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health.  The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and the 505(b)(2) regulatory pathway.  Juniper's core operating business includes the Crinone^® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients.  Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Contact
Amy Raskopf
Director, Corporate Communications, Juniper Pharmaceuticals, Inc.
(917) 673-5775 / ir@juniperpharma.com

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.

Follow us on LinkedIn  

Logo - http://photos.prnewswire.com/prnh/20150527/218998LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-to-report-third-quarter-2016-results-on-november-15-2016-300362417.html

SOURCE Juniper Pharmaceuticals, Inc.